Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer

Table 2 Investigational medicinal products used in the FIRE-8 trial during first-line treatment

Study Arm	IMP	Dose	Dosing schedule (day of 28-day cycle)	Administration
A and B	Trifluridine/ tipiracil	35 mg/m²/dose BID	1–5 and 8–12	orally
A	Panitumumab	6 mg/kg body weight	1 and 15	i.v. over 30–60 min^a
B	Bevacizumab	5 mg/kg body weight	1 and 15	i.v. over 60 ± 15 min^b

IMP Investigational medicinal product, i.v. intravenous infusion, BID twice daily
^afirst administration over 60 min; ^bfirst administration over 90 ± 15 min

ISSN: 1471-2407